My main point was that the two agreements had nothing to do with each other, which was his question. That lead to the rest which is that this is a company without internal R&D at this point. EC brought the continued VCU work to my attention last night, which I acknowledged and admit to being wrong about not thinking that they'd keep doing the R&D on 5HMF.
With that said, what I'm getting at is who's going to make 5HMF into something someone can sell? First of all, NIPRD developed Niprisan, which then became Nicosan and Hemoxin for the purposes of actually selling a product with the work done by Xechem Nigeria (and NIPRD, of course). As you say, 5HMF is a compound found in Niprisan/Nicosan/Hemoxin, which has since been given a patent and is being discussed as a future treatment by itself. VCU has been doing toxicology work on the product and development continues. Xechem International owns the worldwide rights to produce, market and sell the product. What product? Who's going to do that work? VCU? Xechem Nigeria? As you said, 5HMF is a compound, can you put it in a package and sell it or is there more work to be done to have a real SCD drug? Or is the plan to have the rights to 5HMF to market to others making SCD drugs? Either way it was smart to do it, I just don't think the current management is thinking long term by outsourcing (or going off shore) all R&D.
I've only posted on here so far because the Yahoo finance board has turned into an insult-fest and I literally found out about the Raging Bull boards today, but have been a bit busy to validate that account. I'm sure there are others, but there are only so many hours in a day... I've been around her for a while, but just reading with no account.
Market Data 
Markets 
